Efficiency of Virtual Reality Exposure Therapy in the Management of Body Dysmorphic Disorders in Female Adolescents With Anorexia Nervosa

Recruiting now · Not applicable

Conditions studied: Anorexia Nervosa

In brief

Anorexia nervosa is defined in DSM V as a quantitative and qualitative dietary restriction resulting in significant weight loss, intense fear of weight gain, altered weight and body shape perception (body dysmorphic disorder) and low self-esteem influenced by weight or body shape. Body dysmorphic disorder is the most difficult symptom to manage in anorexia nervosa and its persistence is a factor associated with relapse. Virtual reality exposure therapy has proven its effectiveness in the management of post-traumatic stress disorder in the military and is a widely used therapy. The effectiveness of this treatment using new technologies has not yet been studied for the treatment of body dysmorphic disorder in anorexia nervosa and is not used routinely. It could represent an interesting alternative to the physical approach in psychomotor therapy, traditionally offered to patients suffering from anorexia nervosa. It is important to evaluate the effectiveness of virtual reality exposure therapy in the management of body dysmorphic disorder in patients with anorexia nervosa by comparing these two care techniques.

Key facts

Study ID

NCT04107870

Run by

CHU de Reims

People needed

40

Starts

2021-06-20

Expected to finish

2028-09-20

Last updated by the study team

2023-03-08

Who can join

Age: 13 and older, up to 17. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female adolescents aged 13 to 18
• with a diagnosis of anorexia nervosa of all types (including purgative and hyperphagic) according to the DSM-V
• French as first language
• agreed to participate in the study
• parental authority holders accepting her participation in the study
• affiliated to a social security system
• Patients will not be included in the study:
• with a somatic severity criterion:
• Total aphagia
• Body mass index (BMI) < 14kg/m² for those over 17 years of age, BMI < 13.2kg/m² for those aged 15-16 and BMI < 12.7kg/m² for those aged 13-14.
• Confusion
• Bradycardia <40/min, Tachycardia
• Blood pressure < 80/50mmHg
• Hypothermia <35.5°C
• Severe metabolic disorders: hypokalemia < 2.5 mmol/l, hyponatremia < 125mmol/l or hypernatremia > 150 mmol/l, hypophosphoremia < 0.5 mmol/l
• Acetonuria, hypoglycemia < 0.6g/l
• Creatinine elevation > 100micromol/l
• Cytolysis > 4N
• Leuconeutropenia <1000/mm3
• Thrombocytopenia <6000000/mm3
• Suicide attempt in the last month before inclusion
• Receiving benzodiazepine treatment outside the prescription limits.
• Psychotic patients or patients with psychoactive substance addiction according to MINI KID criteria (Sheehan DV et al. Reliability and validity of the Mini International Neuropsychiatric Interview for children and adolescents (MINI Kid). J Clin Psychiatry 2010;71(3):313-326).

Where it is running

• Damien JOLLY — Reims, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.